These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 2677298)

  • 41. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages.
    Alvarez M; Casadevall A
    Curr Biol; 2006 Nov; 16(21):2161-5. PubMed ID: 17084702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.
    Alvarez M; Saylor C; Casadevall A
    Cell Microbiol; 2008 Aug; 10(8):1622-33. PubMed ID: 18384661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunology of infection caused by Cryptococcus neoformans.
    Wormley FL; Perfect JR
    Methods Mol Med; 2005; 118():193-8. PubMed ID: 15888944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro effect of lung surfactant on alveolar macrophage defence mechanisms against Cryptococcus neoformans.
    Gross NT; Camner P; Chinchilla M; Jarstrand C
    Mycopathologia; 1998-1999; 144(1):21-7. PubMed ID: 10422270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ingestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form.
    Cross CE; Bancroft GJ
    Infect Immun; 1995 Jul; 63(7):2604-11. PubMed ID: 7790075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.
    Diamond RD; May JE; Kane MA; Frank MM; Bennett JE
    J Immunol; 1974 Jun; 112(6):2260-70. PubMed ID: 4596700
    [No Abstract]   [Full Text] [Related]  

  • 47. Experimental and calculated parameters on particle phagocytosis by alveolar macrophages.
    Camner P; Lundborg M; Låstbom L; Gerde P; Gross N; Jarstrand C
    J Appl Physiol (1985); 2002 Jun; 92(6):2608-16. PubMed ID: 12015380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo interaction between alveolar macrophages and Cryptococcus neoformans.
    Nessa K; Gross NT; Jarstrand C; Johansson A; Camner P
    Mycopathologia; 1997; 139(1):1-7. PubMed ID: 9511230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans.
    Griffin FM
    Proc Natl Acad Sci U S A; 1981 Jun; 78(6):3853-7. PubMed ID: 7022456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth inhibition of Cryptococcus neoformans by cloned cultured murine macrophages.
    Kitz DJ; Johnson CR; Kobayashi GS; Medoff G; Little JR
    Cell Immunol; 1984 Oct; 88(2):489-500. PubMed ID: 6386187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages.
    Swenson FJ; Kozel TR
    Infect Immun; 1978 Sep; 21(3):714-20. PubMed ID: 361575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes.
    Davies SF; Clifford DP; Hoidal JR; Repine JE
    J Infect Dis; 1982 Jun; 145(6):870-4. PubMed ID: 7045251
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activated neutrophils exhibit enhanced phagocytosis of Cryptococcus neoformans opsonized with normal human serum.
    Kozel TR; Pfrommer GS; Redelman D
    Clin Exp Immunol; 1987 Oct; 70(1):238-46. PubMed ID: 2961491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide.
    McGaw TG; Kozel TR
    Infect Immun; 1979 Jul; 25(1):262-7. PubMed ID: 383615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitative analysis of phagocytosis of Cryptococcus neoformans by adherent phagocytic cells by fluorescence multi-well plate reader.
    Walenkamp AM; Scharringa J; Schramel FM; Coenjaerts FE; Hoepelman IM
    J Microbiol Methods; 2000 Mar; 40(1):39-45. PubMed ID: 10739341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phagocytosis of Histoplasma capsulatum yeasts and microconidia by human cultured macrophages and alveolar macrophages. Cellular cytoskeleton requirement for attachment and ingestion.
    Newman SL; Bucher C; Rhodes J; Bullock WE
    J Clin Invest; 1990 Jan; 85(1):223-30. PubMed ID: 2104879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Capsular specific IgM enhances complement-mediated phagocytosis and killing of Cryptococcus neoformans by methamphetamine-treated J774.16 macrophage-like cells.
    Aslanyan L; Ekhar VV; DeLeon-Rodriguez CM; Martinez LR
    Int Immunopharmacol; 2017 Aug; 49():77-84. PubMed ID: 28551495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages.
    Vecchiarelli A; Pietrella D; Dottorini M; Monari C; Retini C; Todisco T; Bistoni F
    Clin Exp Immunol; 1994 Nov; 98(2):217-23. PubMed ID: 7955525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phagocytosis of Cryptococcus neoformans by alveolar macrophages.
    Bulmer GS; Tacker JR
    Infect Immun; 1975 Jan; 11(1):73-9. PubMed ID: 1090528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.
    Kelly RM; Chen J; Yauch LE; Levitz SM
    Infect Immun; 2005 Jan; 73(1):592-8. PubMed ID: 15618199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.